drugset / Trial / NCT02020031

Regional Prophylactic Vancomycin in Revision Total Knee Replacement

NCT02020031

Phase 2/3 Completed 22 enrolled Mayo Clinic Vidacare Corporation · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether or not giving a lower dose of antibiotics (Vancomycin) in the area where it is needed (the knee joint) is more effective at preventing infection than the current standard dose which is given intravenously (IV) through a wrist vein.

Timeline

Start
2013-12
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified 500 mg Other
Subject Vancomycin Other / unclassified 1 g Other

Indications